Skip to content

Kodiak Sciences Inc KOD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.83B+49.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.38B+31.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$2.68B+66.8%
Bausch + Lomb logo
Bausch + LombBLCO
$8.58B+1.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Glaukos logo
GlaukosGKOS

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's additional paid-in capital?
Kodiak Sciences Inc (KOD) reported additional paid-in capital of $1.73B in Q1 2026.
How has Kodiak Sciences Inc's additional paid-in capital changed year-over-year?
Kodiak Sciences Inc's additional paid-in capital increased by 15.6% year-over-year, from $1.5B to $1.73B.
What is the long-term trend for Kodiak Sciences Inc's additional paid-in capital?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's additional paid-in capital has grown at a 8.3% compound annual growth rate (CAGR), from $1.15B to $1.72B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.